Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Turning Point Therapeutics, Inc.
Hoffmann-La Roche
Theseus Pharmaceuticals
Centocor, Inc.